Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

about

Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers.Maribavir: a novel antiviral agent with activity against cytomegalovirus.

P2860

Q34511634-BDCB69B6-6BF0-41BB-9FD6-6A0F47EEE6C2 Q37242251-2CF17D6E-8BB6-41BC-8B41-DB9327659D67

P2860

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

Item

http://www.wikidata.org/entity/Q36593846

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

@ast

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

@en

type

Item

label

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

@ast

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

@en

prefLabel

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

@ast

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

@en

P1476

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

@en

P2093

Carolyn Dougherty

http://www.w3.org/2001/XMLSchema#string

D Ronald Goldwater

http://www.w3.org/2001/XMLSchema#string

Mary Schumacher

http://www.w3.org/2001/XMLSchema#string

Stephen A Villano

http://www.w3.org/2001/XMLSchema#string

P2860

Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication

Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults

Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers

Maribavir (ViroPharma).

Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms.

Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action.

Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding

The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress

Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects.

P304

1794-1798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00951-07

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18316526

http://www.w3.org/2001/XMLSchema#string

P932

2346655

http://www.w3.org/2001/XMLSchema#string

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

about

P2860

P2860

Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932